URCH Publishing: Just 100 Drugs Account for More Than One-Third of $808Bn Pharmaceutical Market

Blockbusters continue to dominate sales notes URCH Publishing.

LONDON--(BUSINESS WIRE)-- Over one third of the $808 billion pharmaceutical market is generated by just 100 drugs, says a new report from URCH Publishing, a leading provider of pharmaceutical industry business information.

The report, Pharmaceutical Market Trends, 2010 - 2014 - Key market forecasts and growth opportunities, which is published today, notes that 125 drugs generate over $1 billion a year in global sales and the top 100 have accumulated sales of $258 billion, accounting for 35.3% of the total pharmaceutical market.

The top 20 pharmaceutical products all generated sales in excess of US$4 billion and accounted for 14.6% of the total pharmaceutical market.

There were a total of seven new blockbuster drugs in 2009, generating combined sales of US$9.8 billion.

However, only three of the top 10 products in 2009 are forecast to increase sales over the next five years as generics bite into their market share. Pfizer/Astellas’ Lipitor, Sanofi-Aventis/BMS’s Plavix, Novartis’ Diovan/Co-Diovan and AstraZeneca’s Seroquel will all lose patent protection in the US by the end of 2012 and suffer a significant loss of sales as a result.

Pfizer had the most blockbuster products with 14 (including five inherited through the acquisition of Wyeth). Pfizer also achieved the greatest share of blockbuster sales with 11.7%.

The global pharmaceutical market is forecast to grow to US$1,033 billion in 2014, an equivalent CAGR of 5.0% over the next five years. The 142 page study says future sales growth will remain limited by cost-containment measures in Europe and high prescription drug co-pays for insured consumers in the US. The contribution to future growth from developing European markets will begin to slow as healthcare funding in those markets begins to reach a plateau, while centralised regulation will limit the pricing for innovative drugs in Europe relative to prices in the US.

“Pharmaceutical Market Trends, 2010 - 2014 - Key market forecasts and growth opportunities (4rd Edition)” is available from URCH Publishing. Find more details at:


About URCH Publishing Ltd (http://www.urchpublishing.com)

URCH Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry.


URCH Publishing
Edwin Bailey,
+44 (0)207 060 1099
email service[@]urchpublishing.com.

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Communications  Publishing  Medical Supplies



Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.